Resmed.
manufacturer of CPAP masks, machines and products that diagnose, treat or help manage respiratory conditions
- Reports this week
- 0
- Active events
- 0
- Connections
- 92
What's happening
Earlier this month
-
Mick Farrell is the CEO of Resmed, while Robert Cohen is VP at Stryker orthopaedic group.Some support1 report
-
Michael J. Farrell, while serving as CEO, sold shares in Resmed on July 9, 2025.Well supported5 reports
-
Wells Fargo, Citigroup, and Royal Bank of Canada all raised their target prices for ResMed on November 1, 2026.Some support1 report
One to three months ago
-
MarketBeat reported analyst ratings for ResMed and Abbott Laboratories on October 1, 2026.Some support1 report
-
ResMed (Australia) emphasized the success of its new product rollouts and R&D investments.Some support3 reports
-
Oura announces partnerships with Dexcom and Resmed for health feature integration, while noting that regulatory uncertainty affects its product scope.Some support1 report
-
Resmed discussed its growth outlook in the Americas, highlighting the use of Snap's automated resupply technology during a meeting with Morgan Stanley.Some support1 report
-
Resmed and Koninklijke Philips NV face market challenges due to reduced need for sleep apnea treatments, coupled with a competitor re-entering the U.S. market.Well supported3 reports
-
Resmed and Milestone Scientific Inc. are being compared by analysts regarding their financial metrics.Some support1 report
-
Ron Taylor is retiring after 21 years of service and is being appointed to a lead director role at Resmed.Some support1 report
-
Resmed and Astral devices faced cost increases and required a $42 million charge, impacting operating margins, according to analysts.Some support1 report
Gone quiet
No new reports in 90+ days-
A company listed on the London Stock Exchange is facing a Class 1 recall notice due to safety concerns, with financial performance reported via market data.Some support1 report
-
On August 1, 2026, key partnerships were established involving MAS, including roles as a central bank partner, a hub for digital identity in Asia, and a driver of growth for medical device companies like Resmed.Some support1 report
-
Resmed announced its utilization of Dawn as a new generative AI health concierge while operating in the Americas, with RBC Capital Markets providing analyst coverage.Some support2 reports
-
Analyst discusses market risks facing ResMed stock.Some support1 report1 development inside
-
Analysts are reviewing Resmed's divestiture and acquisition strategy, noting long-term benefits despite near-term EPS dilution.Some support1 report1 development inside
-
Resmed is headquartered in San Diego, California.Some support1 report
-
Resmed sold its MatrixCare business to Frazier Healthcare Partners on July 1, 2026.Some support1 report1 development inside
-
Resmed released its financial results after the New York Stock Exchange closed.Some support2 reports
-
Zacks Investment Research provided stock analysis and ratings for ResMed (Australia) on August 27, 2025.Some support3 reports
-
Justin Leong was appointed Chief Product Officer at ResMed.Some support1 report
-
ResMed (Australia) received a rating upgrade following an upward trend in its earnings estimates on June 26, 2025.Speculative1 report
-
ResMed shares outperformed the S&P 500 on August 28, 2025.Well supported3 reports
-
The industry growth forecast is 8.2%, and ResMed's specific forecast is 7.1%.Some support1 report
-
Investors focused on stock price and earnings trends involving Momentum (Q68797150) and ResMed (Australia) on July 24, 2025.Some support1 report
-
ResMed (Australia) tracked overall market performance on July 15, 2025.Some support1 report
-
Akebia Therapeutics' earnings outlook improved and was noted for outperforming peers, while ResMed was also reported for outperforming the medical sector.Some support1 report
-
ResMed outperformed sector and industry averages by 16.9% and holds a Value Score of C, according to Zacks Medical.Some support2 reports
-
Getinge AB, ResMed (Australia), and Koninklijke Philips N.V. are leading the ventilator market through innovation.Some support2 reports
-
Resmed reported revenue increases for devices and masks in Europe in August 2025.Some support1 report
-
Resmed operates its SaaS business in the United States and Germany.Some support2 reports
-
Resmed announced board appointments and executive changes on August 19, 2025, including Nicole Mowad-Nassar joining the board.Some support1 report
-
Resmed conducted a study projecting a rise in Obstructive Sleep Apnea (OSA) in the US, with CMO Carlos Nunez as a co-author.Some support1 report1 development inside
-
Resmed announced details about AirTouch N30i, a nasal cradle mask product designed to help patients manage Obstructive Sleep Apnea (OSA).Some support2 reports
-
The World Sleep Congress is being held in Singapore on September 4, 2025, involving Resmed.Some support1 report1 development inside
-
Resmed reported 11% top-line growth in Europe, alongside strong performance in the U.S. and Canada.Some support1 report
No events began in the chosen period. Widen it, or reset.
What's reaching Resmed
Events traced to Resmed, step by step, newest firstAround Resmed this week
News at the entities that move Resmed most-
FDA StructuralFDA issued a warning letter to NeoGen regarding a product quality defect on October 7, 2026.Moves Resmed
-
London Stock Exchange StructuralShares were purchased on the London Stock Exchange on November 12, 2026.Moves Resmed
-
Morgan Stanley OperationalMorgan Stanley and JPMorgan Chase issued similar preferred dividend declarations on November 1, 2026.Moves Resmed
-
inflation Structural221 US trucking companies filed for bankruptcy following high operating costs and weak revenue.Moves Resmed
-
Wells Fargo Mentioned togetherWells Fargo paid fines related to SEC actions concerning misconduct uncovered by whistleblower Michael Bacon.Moves Resmed
-
Citigroup Mentioned togetherMorgan Stanley and Citigroup cut AutoNation's rating and price objective on November 6, 2026.Moves Resmed
Connections
The 36 strongest of 92, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Mick Farrell Structural
Mick Farrell holds the formal leadership roles of Chairman and CEO at Resmed.
-
Michael J. Farrell Structural
Michael J. Farrell holds the executive role of CEO at Resmed.
-
London Stock Exchange Structural
Resmed is publicly traded on the London Stock Exchange, relying on its infrastructure for market valuation and liquidity.
-
Michael Farrell Structural
Michael Farrell serves as the CEO of Resmed.
-
Dawn Structural
Resmed utilizes Dawn as a generative AI health concierge service.
-
Michael Farrell Structural
A's professional actions are described as driving the growth of the medical device company B in Singapore.
-
Dawn Structural
Dawn functions as a generative AI agent for Resmed.
-
New York Stock Exchange Structural
Resmed operates as a publicly traded company whose market functions are governed by the rules of the New York Stock Exchange.
Show all 36 connections
-
FDA Structural
The FDA regulates Resmed, resulting in an investigation and a Class 1 recall notice.
-
Koninklijke Philips NV Operational
The two companies are potential competitors facing re-entry into the U.S. medical device market.
-
Oura Operational
Oura and Resmed have formed a partnership to integrate health features into their respective products.
-
Astral Transactional
Resmed has taken a charge for devices supplied by Astral, which are currently facing safety concerns and recall.
-
Baxter International Operational
The two companies are actively competing within the specialized healthcare equipment market segment.
-
Morgan Stanley Operational
Morgan Stanley influenced ResMed's market standing by issuing a stock downgrade citing profit margin concerns.
-
Snap Inc. Structural
Resmed is integrating Snap's automated resupply technology into its operations.
-
Tyler Reddick Operational
Tyler Reddick collaborates with Resmed to promote health awareness.
-
Wells Fargo Mentioned together
Wells Fargo provides financial analysis and target price ratings for Resmed.
-
Royal Bank of Canada Mentioned together
RBC provides investment analysis and price targets for Resmed shares.
-
Dexcom Mentioned together
Both companies are grouped thematically within the healthcare equipment segment.
-
Europe Shared context
Resmed reports financial growth and revenue increases within the European market.
-
RBC Capital Markets Mentioned together
RBC Capital Markets provides analyst coverage and rating updates on Resmed.
-
Medicare Operational
The scale and operational dynamics of the Medicare program influence the cost structure and premium increases relevant to Resmed's market.
-
WHOOP Operational
The relationship is based on partnerships where users are referred to Resmed products.
-
inflation Structural
Inflationary pressures manifest as cost increases that directly impact Resmed's operating margins.
-
Abbott Laboratories Mentioned together
Both Abbott Laboratories and Resmed are categorized as large-cap healthcare companies.
-
Americas Shared context
Resmed conducts business operations within the Americas market segment.
-
Osa Shared context
Resmed develops masks for the treatment of Obstructive Sleep Apnea (OSA).
-
Indiana Shared context
Resmed is expanding facilities within the state of Indiana.
-
William Blair Transactional
The relationship is characterized by an analyst's view regarding a divestiture, which is viewed as a long-term benefit.
-
San Diego Shared context
ResMed is headquartered in San Diego, California.
-
Goldman Sachs Mentioned together
Both companies were mentioned in the context of analysts seeking clarity on revenue growth drivers.
-
Citigroup Mentioned together
Citigroup has provided a financial target price assessment for Resmed.
-
North America Shared context
Resmed operates within North America, optimizing its delivery timelines across the region.
-
Social Security Shared context
Resmed operates within the broader healthcare market context influenced by Social Security's benefit structure.
-
Robert Cohen Mentioned together
No direct relationship between Robert Cohen and Resmed was observed in the provided evidence.
-
Peter Switzer Mentioned together
The evidence is insufficient to define a relationship between Peter Switzer and Resmed beyond a potential, unproven market context.
History
Events by the month they beganNovember 2026
2 eventsOctober 2026
1 eventSeptember 2026
3 events- Oura announces partnerships with Dexcom and Resmed for health feature integration, while noting that regulatory uncertainty affects its product scope.
- Resmed discussed its growth outlook in the Americas, highlighting the use of Snap's automated resupply technology during a meeting with Morgan Stanley.
- Resmed and Milestone Scientific Inc. are being compared by analysts regarding their financial metrics.
Show 3 earlier months
August 2026
5 events- Ron Taylor is retiring after 21 years of service and is being appointed to a lead director role at Resmed.
- Resmed and Astral devices faced cost increases and required a $42 million charge, impacting operating margins, according to analysts.
- A company listed on the London Stock Exchange is facing a Class 1 recall notice due to safety concerns, with financial performance reported via market data.
- On August 1, 2026, key partnerships were established involving MAS, including roles as a central bank partner, a hub for digital identity in Asia, and a driver of growth for medical device companies like Resmed.
- Resmed announced its utilization of Dawn as a new generative AI health concierge while operating in the Americas, with RBC Capital Markets providing analyst coverage.
July 2026
4 events- Analyst discusses market risks facing ResMed stock.
- Analysts are reviewing Resmed's divestiture and acquisition strategy, noting long-term benefits despite near-term EPS dilution.
- Resmed is headquartered in San Diego, California.
- Resmed sold its MatrixCare business to Frazier Healthcare Partners on July 1, 2026.
June 2026
21 events- Michael J. Farrell, while serving as CEO, sold shares in Resmed on July 9, 2025.
- ResMed (Australia) emphasized the success of its new product rollouts and R&D investments.
- Resmed and Koninklijke Philips NV face market challenges due to reduced need for sleep apnea treatments, coupled with a competitor re-entering the U.S. market.
- Resmed released its financial results after the New York Stock Exchange closed.
- Zacks Investment Research provided stock analysis and ratings for ResMed (Australia) on August 27, 2025.
- Justin Leong was appointed Chief Product Officer at ResMed.
- ResMed (Australia) received a rating upgrade following an upward trend in its earnings estimates on June 26, 2025.
- ResMed shares outperformed the S&P 500 on August 28, 2025.
- The industry growth forecast is 8.2%, and ResMed's specific forecast is 7.1%.
- Investors focused on stock price and earnings trends involving Momentum (Q68797150) and ResMed (Australia) on July 24, 2025.
- ResMed (Australia) tracked overall market performance on July 15, 2025.
- Akebia Therapeutics' earnings outlook improved and was noted for outperforming peers, while ResMed was also reported for outperforming the medical sector.
- ResMed outperformed sector and industry averages by 16.9% and holds a Value Score of C, according to Zacks Medical.
- Getinge AB, ResMed (Australia), and Koninklijke Philips N.V. are leading the ventilator market through innovation.
- Resmed reported revenue increases for devices and masks in Europe in August 2025.
- Resmed operates its SaaS business in the United States and Germany.
- Resmed announced board appointments and executive changes on August 19, 2025, including Nicole Mowad-Nassar joining the board.
- Resmed conducted a study projecting a rise in Obstructive Sleep Apnea (OSA) in the US, with CMO Carlos Nunez as a co-author.
- Resmed announced details about AirTouch N30i, a nasal cradle mask product designed to help patients manage Obstructive Sleep Apnea (OSA).
- The World Sleep Congress is being held in Singapore on September 4, 2025, involving Resmed.
- Resmed reported 11% top-line growth in Europe, alongside strong performance in the U.S. and Canada.